SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales for the March 2022 quarter moved up 45.20% to Rs. 24950.30 millions as compared to Rs. 17183.90 millions during the corresponding quarter last year.Net profit for the quarter ended March 2022 increased significantly by 80.96% to Rs. 8829.60 millions from Rs. 4879.30 millions.Operating profit for the quarter ended March 2022 rose to 11464.80 millions as compared to 7222.00 millions of corresponding quarter ended March 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 24950.30 17183.90 45.20 88798.20 67986.10 30.61 88798.20 67986.10 30.61
Other Income 505.10 228.50 121.05 1112.60 625.30 77.93 1112.60 625.30 77.93
PBIDT 11464.80 7222.00 58.75 39877.20 28832.10 38.31 39877.20 28832.10 38.31
Interest 0.40 1.80 -77.78 6.50 6.90 -5.80 6.50 6.90 -5.80
PBDT 11464.40 7220.20 58.78 39870.70 28825.20 38.32 39870.70 28825.20 38.32
Depreciation 807.50 698.40 15.62 3105.50 2546.50 21.95 3105.50 2546.50 21.95
PBT 10656.90 6521.80 63.40 36765.20 26278.70 39.90 36765.20 26278.70 39.90
TAX 1827.30 1642.50 11.25 7279.80 6731.50 8.15 7279.80 6731.50 8.15
Deferred Tax 380.40 288.50 31.85 907.80 641.00 41.62 907.80 641.00 41.62
PAT 8829.60 4879.30 80.96 29485.40 19547.20 50.84 29485.40 19547.20 50.84
Equity 530.90 530.90 0.00 530.90 530.90 0.00 530.90 530.90 0.00
PBIDTM(%) 45.95 42.03 9.33 44.91 42.41 5.89 44.91 42.41 5.89

Divis Lab Share Price

6228.95 -68.55 (-1.09%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×